This program, promoted by La Caixa, Barcelona Activa, Biocat, Fundación Genoma España and Barcelona Chamber of Commerce, aims to ease the creation of a company through a series of training activities and analysis of the feasibility of business ideas.

VCN Biosciences, a company promoted by the IDIBELL researchers Manel Cascallo, Ramon Alemany, and Gabriel Capellá, develops new biotechnology drugs with high potency and selectivity to cope with cancer by oncolytic adenoviruses. The action system of the oncolytic viruses is selective tumor cell proliferation, which causes its death.